Long-term changes in adiposity markers during and after antidepressant therapy in a community cohort.

Détails

ID Serval
serval:BIB_9B98DC0FE18C
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Long-term changes in adiposity markers during and after antidepressant therapy in a community cohort.
Périodique
Translational psychiatry
Auteur⸱e⸱s
Mwinyi J., Strippoli M.F., Kanders S.H., Schiöth H.B., Eap C.B., Lasserre A.M., Marques-Vidal P., Vandeleur C.L., Preisig M.
ISSN
2158-3188 (Electronic)
ISSN-L
2158-3188
Statut éditorial
Publié
Date de publication
13/08/2024
Peer-reviewed
Oui
Volume
14
Numéro
1
Pages
330
Langue
anglais
Notes
Publication types: Journal Article
Publication Status: epublish
Résumé
Research on antidepressant-related weight changes over more than 12 months is scarce and adjustment for the effects of depressive episodes has rarely been applied. Accordingly, our aim was to assess the associations of the use of any antidepressants, subclasses of antidepressant and specific compounds prior to baseline and during a 5.5-year follow-up with changes in adiposity markers, and the effect of sex on these associations, with adjustment for multiple confounders including the effects of depressive episodes and their severity. Data stemmed from a prospective cohort study including 2479 randomly selected 35-66 year-old residents of an urban area (mean age 49.9 years, 53.3% women) who underwent physical and psychiatric evaluations at baseline and follow-up. Weight, height, waist circumference, and body fat were measured by trained nurses and information on diagnosis and antidepressant use prior to baseline and during follow-up was collected through standardized interviews. In the fully adjusted models, the number of antidepressants, mainly SSRIs and TCAs, used prior to baseline, was associated with a lower increase of body-mass index (BMI, β (95%CI) = -0.12 (-0.19, -0.05)) and waist circumference (β = -0.28 (-0.56, -0.01)), whereas participants treated with antidepressants during the follow-up had a steeper increase in BMI (β = 0.32 (0.13, 0.50)) and waist circumference (β = 1.23 (0.44, 2.01)). Within the class of SSRIs, the use of fluoxetine, sertraline or escitalopram during follow-up was associated with a steeper increase in adiposity markers. The associations of SSRIs with BMI and waist circumference were only observed when the SSRIs were used during the second period of the follow-up. Sex did not moderate these associations. Our findings suggest an increase of adiposity markers during sustained treatment with TCAs and SSRIs, which however return to normal levels after cessation of treatment. Hence, the benefit of long-term administration of these antidepressants should be carefully weighed against the potential risk of weight gain.
Mots-clé
Humans, Male, Female, Middle Aged, Adiposity/drug effects, Antidepressive Agents/therapeutic use, Adult, Aged, Waist Circumference, Prospective Studies, Body Mass Index, Follow-Up Studies, Selective Serotonin Reuptake Inhibitors/therapeutic use
Pubmed
Web of science
Open Access
Oui
Création de la notice
19/08/2024 8:59
Dernière modification de la notice
20/08/2024 6:23
Données d'usage